Duration of protection from clinical hepatitis A disease after vaccination with VAQTA®

Journal of Medical Virology

Volumn 49, Issue 3, 1996, Pages 235-241

  Wiens, Brian L ^a   Bohidar, Norman R ^a   Pigeon, Joseph G ^b   Egan, James ^c,d   Hurni, William ^a   Brown, Leora ^a   Kuter, Barbara J ^a   Nalin, David R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b VILLANOVA UNIVERSITY   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d FITZSIMONS ARMY MEDICAL CENTER   (United States)

Author keywords

anamnestic response; antibody; extrapolation; hepatitis A virus

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CALCULATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEPATITIS A; HUMAN; MAJOR CLINICAL STUDY; MALE; REVACCINATION; VACCINATION;

HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS ANTIBODIES; HUMANS; TIME FACTORS; VACCINATION; VACCINES, INACTIVATED; VIRAL HEPATITIS VACCINES;

HEPATITIS A VIRUS;

EID: 0029743994     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199607)49:3<235::AID-JMV13>3.0.CO;2-B     Document Type: Article

References (21)

1. Berger R, Just M, Althaus B (1993): Time course of hepatis A antibody production after active, passive and active/passive immunization: The results are highly dependent on the antibody test system used. Journal of Virological Methods 43:267-297.
2. Block SL, Hedrick JA, Tyler RD, Smith RA, Calandra GB, Patterson C, Lewis J, Sitrin R, Miller W, Schwartz S, Wiens BL, Nalin DR (1993): Safety, tolerability and immunogenicity of a formalin inactivated hepatitis A vaccine trial in rural Kentucky children. Pediatric Infectious Disease Journal 12:976-980.
3. Conrad ME, Lemon SM (1987): Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. Journal of Infectious Diseases 156:56-63.
4. Davidson M, Krugman S, Sandman LA (1992): Inactivated hepatitis A vaccine: Safety and immunogenicity study in health professionals. Vaccine 10 (Supplement 1):S119-S120.
5. Egan J, Nalin D, Lewis J, Mitchell D, Sjogren M, Patterson C, Wiens B, Murray P, Kay J, Hoke C (1993): Safety and immunogenicity of hepatitis A vaccine. Proceedings of 1993 International Symposium on Viral Hepatitis and Liver Disease, Tokyo, Japan, May 14, 1993, Abstract 33, p 106.
6. Hadler SC (1991): Global impact of hepatitis A virus infection: Changing patterns. In Hollinger FB, Lemon SM, Margolis H (eds): "Viral Hepatitis and Liver Disease: Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects." Baltimore: Williams and Wilkins, pp 14-20.
7. Kuter B, Bishop R, Falcone R, Nalin D, Belliel S, Clark W, Miller W, Lewis J, Calandra G, Ryan J (1991): Safety and immunogenicity of inactivated hepatitis A vaccine in healthy adults. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 31st Annual Meeting (ICAAC), Chicago, Illinois, Sept 29-Oct 2, 1991, Abstract 1098, p 282.
8. Midthun K, Ellerbeck E, Gershman K, Nalin D, Provost P (1991): Safety and immunogenicity of a live attenuated hepatitis A vaccine in seronegative volunteers. Journal of Infectious Diseases 163: 735-739.
9. Midthun K, Ellerbeck E, Clements ML, Shahan J, Patterson C, Clark W, Nalin D (1992): Persistence of hepatitis A virus antibody 24 months after immunization with an inactivated hepatitis A virus vaccine. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy 32nd Annual Meeting, Anaheim, California, Oct 11-14, 1992.
10. Miller WJ, Clark W, Hurni W, Kuter B, Schofield T, Nalin D (1993): Sensitive assays for hepatitis A antibodies. Journal of Medical Virology 41:201-204.
11. Mood AM, Graybill FA, Boes DC (1974): "Introductions to the Theory of Statistics." New York: McGraw-Hill, pp 512-514.
12. Nalin DR (1995): VAQTA®: Hepatitis A vaccine, purified inactivated. Drugs of the Future 20(1):24-29.
13. Newcomer W, Rivin B, Reid R, Moulton LH, Wolff M, Croll J, Johnson C, Brown L, Nalin D, Santosham M (1994): Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus (HAV) vaccine in Navajo children. Pediatric Infectious Disease Journal 13:640-642.
14. Schofield T, Lei CM (1988): Modeling Antibody Persistence. Eleventh Annual Midwest Biopharmaceutical Statistics Workshop, Muncie, Indiana, May 26, 1988.
15. Shouval D, Ashur Y, Adler R, Lewis JA, Armstrong ME, Davide JP, Roi M, Daudi N, Elkana Y, McGuire B, Kuter B, Brown L, Patterson C, Miller W, Rhoad AE, Calandra GB, Nalin DR, Ryan J (1993): Single and booster dose responses to an inactivated hepatitis A virus vaccine: Comparison with immune serum globulin prophylaxis. Vaccine 11 (Supplement 1):S9-S14.
16. Tilzey AJ, Palmer SJ, Barrow S, Perry KR, Tyrell H, Safary A, Banatvala JE (1992): Effect of hepatitis A vaccination schedules on immune response. Vaccine 10 (Supplement 1):S121-S123.
17. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A (1994): Inactivated hepatitis a vaccine: Reactogenicity, immunogenicity, and long-term antibody persistence. Journal of Medical Virology 44:446-451.
18. Villarejos VM, Jaime Serro C, Anderson-Visona K, Mosley JW (1982): Hepatitis A virus infection in households. American Journal of Epidemiology 115(4):577-586.
19. Ward R, Krugman S, Giles JP, Jacobs AM, Bodansky O (1958): Infectious hepatitis: studies of its natural history and prevention. New England Journal of Medicine 258:407-416.
20. Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens A, Calandra G, Ryan J, Provost P, Nalin D (1992): A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. New England Journal of Medicine 327:453-457.
21. Wiedermann G, Ambrosch F, Andre FE, D'Hondt E, Delem A, Safary A (1992): Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 10 (Supplement 1):S129-S131.